An Olmesartan Medoxomil-Based Treatment Algorithm is Effective in Achieving 24-Hour BP Control in Patients with Type 2 Diabetes Mellitus, Regardless of Age, Race, Sex, or Severity of Hypertension: Subgroup Analysis of the BENIFICIARY Study

By Neutel Joel M.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. : 289-303

Adis International

Access to resources Recommend Favorite

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study

By Kereiakes Dean J.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 239-246

Adis International

Access to resources Recommend Favorite

Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study

By Schmidt Andre C.  

Clinical Drug Investigation, Vol. 27, Iss. 12, 2007-01 ,pp. : 841-849

Adis International

Access to resources Recommend Favorite

Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil/Hydrochlorothiazide-Based Treatment Algorithm in Elderly Patients (Age ≥65 Years) Stratified by Age, Sex and Race: Subgroup Analysis of a 12-Week, Open-Label, Single-Arm, Dose-Titration Study

By Neutel Joel  

Drugs & Aging, Vol. 28, Iss. 6, 2011-06 ,pp. : 477-490

Adis International

Access to resources Recommend Favorite

Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring: Efficacy in High-Risk Patient Subgroups

By Chrysant Steven G.  

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 6, 2012-12 ,pp. : 375-389

Adis International

Access to resources Recommend Favorite